BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.

BACKGROUND Mutations in BRCA1 and/or BRCA2 (BRCA1/2) profoundly increase the risks of breast and ovarian cancers, but it is unclear whether mutations in these genes increase the risk of colorectal cancer. We investigated BRCA1/2 founder mutations and a family history of breast cancer as potential risk factors for colorectal cancer. METHODS In the population-based Molecular Epidemiology of Colorectal Cancer study in northern Israel, 1422 case patients with incident colorectal cancer, diagnosed between March 31, 1998, and December 31, 2002, and 1566 control subjects without colorectal cancer were genotyped for the BRCA1 187delAG, BRCA1 5385insC, and BRCA2 6174delT founder mutations. Genotypes and interview data from all case patients and control subjects and from only those of Ashkenazi Jewish descent (1002 case patients and 1038 control subjects) were used to calculate odds ratios [ORs] from logistic regression. RESULTS Twenty-four (2.4%) case patients and 20 (1.9%) control subjects carried one of the three mutations (OR = 1.24, 95% confidence interval [CI] = 0.68 to 2.26). A family history of breast cancer in a female relative was not associated with an increased risk of colorectal cancer, even after adjustment for the presence of a BRCA founder mutation (OR = 1.03, 95% CI = 0.75 to 1.41). CONCLUSIONS Although weak associations cannot be excluded, Ashkenazi BRCA founder mutations do not confer a strongly elevated risk of colorectal cancer. Similarly, a family history of breast cancer does not appear to be a strong risk factor for colorectal cancer in this population.

[1]  I. Lerer,et al.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. , 1997, American journal of human genetics.

[2]  L. Drucker,et al.  Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. , 2000, Anticancer research.

[3]  S. Gruber Assay for Detecting the I1307K Susceptibility Allele within the Adenomatous Polyposis ColiGene. , 2001, Methods in molecular medicine.

[4]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[5]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[6]  S Wacholder,et al.  The kin-cohort study for estimating penetrance. , 1998, American journal of epidemiology.

[7]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[8]  M. King,et al.  The APC I1307K allele and breast cancer risk , 1998, Nature Genetics.

[9]  M. Slattery,et al.  Comparison of self-reported and database-linked family history of cancer data in a case-control study. , 1997, American journal of epidemiology.

[10]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[11]  E. Friedman,et al.  The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients , 2001, British Journal of Cancer.

[12]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[13]  T. Sellers,et al.  Evaluation of potential sources of bias in a genetic epidemiologic study of breast cancer , 1997, Genetic epidemiology.

[14]  D. Brogan,et al.  Characteristics of respondents and non-respondents from a case-control study of breast cancer in younger women. , 2000, International journal of epidemiology.

[15]  Phipps Rf,et al.  Familial breast cancer and the association with colonic carcinoma. , 1989 .

[16]  M. Slattery,et al.  Family history of cancer and colon cancer risk: the Utah Population Database. , 1994, Journal of the National Cancer Institute.

[17]  R K Craig,et al.  Methods in molecular medicine. , 1987, British medical journal.

[18]  P. Hartge,et al.  The APC I1307K allele and cancer risk in a community-based study of Ashkenazi Jews , 1998, Nature Genetics.

[19]  D. Fishman,et al.  BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. , 2000, American journal of human genetics.

[20]  E. Thomson,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 , 1997 .

[21]  E. Thomson,et al.  Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer , 1997 .

[22]  T. Sellers,et al.  Familial clustering of colon, breast, uterine, and ovarian cancers as assessed by family history , 1993, Genetic epidemiology.

[23]  H. Olsson Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[24]  R. Love,et al.  The accuracy of patient reports of a family history of cancer. , 1985, Journal of chronic diseases.

[25]  C. Eng Will the real Cowden syndrome please stand up: revised diagnostic criteria , 2000, Journal of medical genetics.

[26]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.

[27]  D. Anderson An inherited form of large bowel cancer. Muir's syndrome , 1980, Cancer.